Improved PFS and OS in HER2-Positive and Triple-Negative Breast Cancer

Four international randomised studies in early HER2-positive and metastatic triple-negative breast cancer show significant improvements in PFS, OS, and invasive disease-free survival. In this article, Hanne Melgaard Nielsen, senior consultant at the Department of Oncology, Aarhus University Hospital, Denmark, presents her perspectives on the results.